Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2, 2004. The report details changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) resulting from movements in employee benefit plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share ownership disclosures rather than financial performance metrics.
Material Changes
- US Retirement Savings Plan: The number of Ordinary Share ADRs held by the fund increased from 18,374,163 to 18,509,239 on January 29, 2004, at an average price of $44.05. A subsequent increase occurred on January 30, 2004, raising the total to 18,560,178 ADRs at an average price of $44.00.
- Directors' Interests: Dr. J P Garnier and Dr. T Yamada reported increases in their potential interests in Ordinary Share ADRs on January 30, 2004, at a price of $44.00 per share. Dr. Garnier's interest increased by 80 shares, and Dr. Yamada's by 38 shares.
- Employee Trust Transfer: On January 30, 2004, Abacus (GSK) Trustees Limited transferred 13,484 Ordinary shares from the GlaxoSmithKline Employee Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves as a regulatory disclosure of share ownership changes.
Important Facts for Investors
- Directors Dr. J P Garnier and Dr. T Yamada hold potential interests in shares held by the US Retirement Savings Plan and the GSK Employee Trust.
- Share price movements in the US Retirement Savings Plan occurred at approximately $44.00 to $44.05 per share in late January 2004.
- A specific transfer of 13,484 Ordinary shares was executed from the GSK Trust to employee option plan participants.